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Abstract
Background: Macrophages constitute a heterogeneous cell population with pro- (MΦ1) and anti-inflammatory
(MΦ2) cells. The soluble chitinase-like-protein YKL-40 is expressed in macrophages and various other cell types, and
has been linked to a variety of inflammatory diseases, including COPD. Dexamethasone strongly reduces YKL-40
expression in peripheral blood mononuclear cells (PBMC) in vitro. We hypothesized that: a) YKL-40 is differentially
expressed by MΦ1 and MΦ2, b) is decreased by corticosteroids and c) that long-term treatment with inhaled
corticosteroids (ICS) affects YKL-40 levels in serum and sputum of COPD patients.
Methods: Monocytes of healthy subjects were cultured in vitro for 7 days with either GM-CSF or M-CSF
(for MΦ1 and MΦ2, respectively) and stimulated for 24 h with LPS, TNFα, or oncostatin M (OSM). MΦ1 and MΦ2
differentiation was assessed by measuring secretion of IL-12p40 and IL-10, respectively. YKL-40 expression in
macrophages was measured by quantitative RT-PCR (qPCR) and ELISA; serum and sputum YKL-40 levels were
analyzed by ELISA.
Results: Pro-inflammatory MΦ1 cells secreted significantly more YKL-40 than MΦ2, which was independent of
stimulation with LPS, TNFα or OSM (p < 0.001) and confirmed by qPCR. Dexamethasone dose-dependently and
significantly inhibited YKL-40 protein and mRNA levels in MΦ1. Serum YKL-40 levels of COPD patients were
significantly higher than sputum YKL-40 levels but were not significantly changed by ICS treatment.
Conclusions: YKL-40 secretion from MΦ1 cells is higher than from MΦ2 cells and is unaffected by further
stimulation with pro-inflammatory agents. Furthermore, YKL-40 release from cultured monocyte-derived
macrophages is inhibited by dexamethasone especially in MΦ1, but ICS treatment did not change YKL-40 serum
and sputum levels in COPD. These results indicate that YKL-40 expression could be used as a marker for MΦ1
macrophages in vitro, but not for monitoring the effect of ICS in COPD.
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Background
YKL-40 (or chitinase 3-like-1 [CHI3L1], breast regres-
sion protein [BRP]-39 or human cartilage glycoprotein-
39 [HC gp-39]) is a chitinase-like protein which is found
in humans [1]. It is expressed by various cell types, in-
cluding neutrophils and macrophages [2–4], while mac-
rophages have been identified as its main cellular source
[2, 5]. Monocytes do not express YKL-40, and YKL-40
expression appears to be associated with later stages of
macrophage differentiation [2, 6]. Although its biological
function is largely unknown, YKL-40 has been suggested
to play a major role in a variety of processes, including
epithelial-mesenchymal transition, migration and prolif-
eration of (malignant) cells, angiogenesis, tissue remod-
eling and inflammation [7–9]. Furthermore, YKL-40 has
been implicated in several acute and chronic inflam-
matory diseases, including asthma and COPD [10, 11].
Several studies have shown that YKL-40 levels are higher
in sputum and serum of COPD patients compared to
asymptomatic smokers [12, 13].
These data suggest that macrophages may also be a
major source of YKL-40 in inflammatory lung diseases
such as COPD, a disease in which macrophages play an
important role [14]. It is however unknown whether YKL-
40 expression is restricted to a subset of macrophages.
This is a relevant question, since macrophages constitute
heterogeneous cell populations with various functions.
Pro-inflammatory, or classically activated macrophages
(type I, MΦ1), show pro-inflammatory properties by se-
creting pro-inflammatory cytokines such as interleukin
(IL)-12, have antigen presenting capacity and promote
Th1 immunity. In contrast, anti-inflammatory, or alterna-
tively activated macrophages (type II, MΦ2), demonstrate
anti-inflammatory characteristics with expression and se-
cretion of anti-inflammatory cytokines, such as IL-10 and
promote development of regulatory T cells [15]. Fur-
thermore, Di Rosa et al. observed higher expression of
YKL-40 in monocyte-derived MΦ1 [16].
Dexamethasone strongly suppresses YKL-40 expres-
sion in cultured monocyte-derived macrophages [17]. In
line with these findings, rheumatoid arthritis patients
treated with methotrexate and prednisolone had lower
serum YKL-40 concentrations compared to patients treated
without prednisolone [18]. However, it is unknown if
YKL-40 levels are influenced by treatment with inhaled
corticosteroids (ICS) in COPD and could therefore be
used to monitor treatment response. Furthermore, it is
not known whether modulation by steroids is a direct gen-
omic anti-inflammatory effect or due to e.g. epigenetic
mechanisms [19–22].
Based on these observations we hypothesized that YKL-
40 expression is directed by macrophage polarization, with
a higher expression in monocyte-derived MΦ1 compared
to MΦ2. Furthermore, we hypothesized that steroids
decrease YKL-40 secretion and expression in MΦ1 and
that YKL-40 in serum and sputum of COPD patients is
decreased by treatment with ICS. The results from this
study show that monocyte-derived MΦ1 secrete and ex-
press more YKL-40 than MΦ2. YKL-40 expression by cul-
tured MΦ1 cells is steroid sensitive as its production is
decreased by dexamethasone. Finally, YKL-40 levels in
sputum and serum do not differ between COPD patients
treated for 30 months with ICS or placebo.
Methods
Cell culture
Monocytes were isolated from buffy coats of healthy blood
donors (Sanquin Blood Bank, Leiden, The Netherlands)
using anti-CD14 microbeads (Miltenyi Biotec, Auburn,
CA, USA) according to the manufacturer’s protocol. MΦ1
and MΦ2 were derived as described previously [23, 24].
Briefly, cells were cultured for six days in RPMI 1640
medium in 48 well plates (Invitrogen, Life Technologies,
Bleiswijk, The Netherlands) containing 10 % fetal calf
serum (FCS, Invitrogen), 2 mM L-glutamine, 100U/ml
penicillin and 100 μg/ml streptomycin (all Bio Whittaker,
Walkersville, MD, USA) at 37 °C in 5 % CO2 atmosphere
with either GM-CSF (5 ng/ml, Invitrogen) or M-CSF
(50 ng/ml, R&D Systems, Minneapolis, MN, USA) to ob-
tain MΦ1 and MΦ2, respectively [13, 14]. Differentiated
macrophages were stimulated with the pro-inflammatory
stimuli lipopolysaccharide (LPS, from Pseudomonas aeru-
ginosa, 100 ng/ml, Sigma-Aldrich, St. Louis, MO, USA),
TNF-α (10 ng/ml, Peprotech, Rocky Hill, NJ, USA) or
oncostatin M (OSM, 100 ng/ml, R&D Systems) for 24 h.
Dexamethasone (0.1, 0.3 and 1nM, Sigma) was added
during differentiation at day 0, 3 and/or day 7. The de-
methylating agent 5-AZA-2’-deoxycytidine (5-AZA, 0.1, 1
and 10 μM, Sigma) was added during differentiation. Every
day 100 μl per well was removed and replaced by fresh
medium containing growth factors and 5-AZA.
GLUCOLD study
Serum and sputum supernatants were obtained from pa-
tients with moderate to severe COPD who participated
in the GLUCOLD (Groningen and Leiden Universities
Corticosteroids in Obstructive Lung Disease) study [25].
Patients were steroid-naive at baseline and were subse-
quently randomized to one of four inhaled treatments,
all twice daily: 6- or 30-month fluticasone propionate
dry-powder inhaler (500 μg, group 1 and 2, respectively),
30-month fluticasone with salmeterol (500/50 μg, group
3) or 30-month placebo (group 4). In this mechanistic
study, we only used data from the compliant patients
(≥70 % of the prescribed dose of treatment) of groups 2
and 3 combined to increase power, and group 4. At base-
line and after 30 months of treatment, serum and sputum
samples were collected. Sputum induction and processing
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were performed as previously described [26, 27]. Cell free
supernatants of serum and sputum were stored at −80 °C.
The ethics committees of Leiden University Medical
Center and University Medical Center Groningen ap-
proved the study and all patients provided written infor-
med consent.
Enzyme-linked Immunosorbent Assay (ELISA)
Commercially available ELISA kits were used to detect
IL-12p40 (IL-12/IL-23p40, R&D Systems; sensitivity
62.5 pg/ml) and IL-10 (Sanquin, Amsterdam, The
Netherlands; sensitivity 4.1 pg/ml), to confirm that the
monocytes were adequately differentiated towards MΦ1
and MΦ2, respectively (Fig. 1a). YKL-40 ELISA (R&D
Systems; sensitivity 16 pg/ml [10]) was performed on
cell culture supernatant, serum and sputum super-
natant. The absorbance was measured at 450 nm using a
Microplate reader (model 680; Bio-Rad, Hercules, CA,
USA) and Microplate Manager software (version 5.2.1,
Bio-Rad).
Fig. 1 Characterization of differentiated MΦ1 and MΦ2. a: IL-12p40 (left panel) and IL-10 (right panel) in supernatants of MΦ1 and MΦ2, respectively,
stimulated with LPS for 24 h. Data represent means with SEM of 6 donors, ** p < 0.01 or *** p < 0.001 between MΦ1 and MΦ2. b: Flow cytometry
analysis for CD68, CD14 and CD163 (left, middle and right panel, respectively) for MΦ1 and MΦ2 (upper and lower panel, respectively)
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Flow cytometry
Cell surface markers were assessed by standard flow
cytometry using a FACS Calibur cytometer (Becton and
Dickinson, La Jolla, CA, USA) and CellQuest Pro soft-
ware after staining with specific APC-conjugated CD163
and CD14 (both BD Biosciences/Pharmingen (Temse,
Belgium), FITC-conjugated CD68 (eBioscience, Vienna,
Austria) and/or goat-anti-human YKL-40 (R&D systems)
detected by Alexa Fluor 594 F(ab’)2 fragment of goat
anti-mouse (Invitrogen) as secondary antibody. Cells
were incubated with the antibodies for 30 min on ice in
PBS containing 0.5 % BSA (w/v) and 0.2 % sodium azide
(w/v) (both Sigma). After fixation with Cytofix/Cytoperm
buffer, intracellular staining was performed in Perm/Wash
buffer (both BD Biosciences). Flow cytometric analysis
confirmed that the differentiated monocytes were CD14+
and CD68+, and that the majority of MΦ2 were CD163+
(Fig. 1b). Therefore, we concluded that the monocytes
were properly differentiated into MΦ1 and MΦ2 cells.
Immunofluorescence staining
YKL-40 and CD68 expression in sputum cytospins was
demonstrated using immunofluorescence. Cytospins were
fixed in 4 % formaldehyde in PBS for 30 min, followed
by antigen retrieval in citrate solution pH6.0 (DAKO,
Glostrup, Denmark) for 30 min and cooled on ice. The
primary antibodies goat-anti-human YKL-40 (R&D sys-
tems, dilution 1:25) and mouse-anti-human CD68 (clone
PG-M1, DAKO, dilution 1:50), diluted in PBS/1 % BSA
(w/v) were incubated together overnight. Alexa Fluor568
donkey-anti-goat and Alexa Fluor 488 donkey-anti-mouse
(Invitrogen, Eugene, Oregon, USA, dilution of both 1:200)
were incubated in a dark environment for 30 min. The
cytospins were covered with Vectashield with DAPI
(Vector Laboratories, Inc. Burlingame, CA, USA). Photo-
graphs were taken with a confocal microscope.
Quantitative reverse-transcriptase polymerase chain
reaction (qPCR)
RNA was isolated using Qiagen RNeasy mini kit (Qiagen,
Venlo, The Netherlands) and cDNA was synthesized
in equal amounts per experiment. Quantitative reverse-
transcriptase polymerase chain reaction (qPCR) was
performed with the primers for YKL-40 and LL-37 as
presented in Table 1. QPCR was performed on the
iCycler PCR device using iQ SYBR Green Supermix
(Bio-Rad) for 40 cycles at 58 °C. Relative mRNA concen-
trations of ACTB and ATP5B (GeNorm, PrimerDesign
Ltd., Southampton, UK) were used as housekeeping genes
for human genes.
Statistical analysis
Differences within one cell type and between cell types
were analyzed by one-way and two-way ANOVA, respect-
ively. Paired and unpaired tests were used for evaluating
YKL-40 levels in serum and sputum within and between
treatments, respectively, using only data from subjects
with availability of samples from both baseline and
30 months. Statistical analysis was performed with SPSS
22.0 software (SPSS Inc., Chicago, IL). Data are presented
as means with standard error of the mean (SEM) for in
vitro experiments and means with standard deviations
(SD) for serum and sputum samples. Differences at p-
values ≤0.05 were inferred as statistically significant.
Results
MΦ1 produce more YKL-40 compared to MΦ2
Secretion of YKL-40 by MΦ1 was markedly higher com-
pared to MΦ2 (p < 0.001) and not further increased by
stimulation for 24 h with 100 ng/ml LPS compared to
medium (p < 0.001; Fig. 2a, left panel). qPCR confirmed
these results, i.e. MΦ1 express more YKL-40 than MΦ2
with and without LPS stimulation (10-fold higher in
MΦ1 vs MΦ2, p < 0.001; Fig. 2a, right panel), with a
trend towards more YKL-40 expression in LPS-stimulated
MΦ1 (p < 0.1). Flow cytometry analysis also showed that
MΦ1 cells express more YKL-40 compared to MΦ2
(Fig. 2b). In addition, MΦ1 secreted more YKL-40 com-
pared to MΦ2 which was irrespective of further stimu-
lation with TNF-α, and OSM for 24 or 48 h, respectively
(all p < 0.001, Fig. 2c). Immunofluorescence staining
showed that only a minority of macrophages in sputum of
COPD patients was positive for YKL-40 as shown by co-
staining with CD68 (Fig. 2d).
YKL-40 expression is inhibited by dexamethasone
To investigate the effect of steroids on macrophage
YKL-40 expression, we first assessed its effect on expres-
sion of the MΦ1 and MΦ2 markers IL-12p40 and IL-10.
Whereas dexamethasone did not affect IL-10 secretion,
it inhibited IL-12p40 secretion, especially when added at
day 0 (Fig. 3a and b, respectively). In line with these
findings, dexamethasone also dose-dependently inhibited
YKL-40 expression and secretion mainly in MΦ1 (Fig. 4a
and b, respectively). Again this effect was most pro-
nounced when dexamethasone was added from the start
Table 1 Primer pairs used for quantitative reverse-transcriptase polymerase chain reaction (qPCR)
Forward Reverse
YKL-40 (CHI3L1)(154 base pairs) CTG TGG GGA TAG TGA GGC AT CTT GCC AAA ATG GTG TCC TT
LL-37 (CAMP)(249 base pairs) TCA TTG CCC AGG TCC TCA G TCC CCA TAC ACC GCT TCA C
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of the differentiation at day 0 (Fig. 4a and b, left panel).
Adding dexamethasone at later time points (day 3 or
day 7) showed a trend for lower YKL-40 expression and
secretion (Fig. 4a and b, middle and right panel, respect-
ively), but failed to reach significance.
We have previously demonstrated that the human
cathelicidin antimicrobial peptide hCAP/LL-37 directs
macrophage differentiation towards MΦ1 cells [28]. In
the course of the latter studies we also noted that
hCAP18/LL-37 is preferentially expressed in MΦ1 cells
Fig. 2 MΦ1 produce more YKL-40 compared to MΦ2. a: YKL-40 secretion measured by ELISA (left panel, 6 donors) and mRNA levels (normalized
expression, right panel, 5 donors) in MΦ1 and MΦ2 after medium and LPS stimulation for 24 h. * p < 0.05 or *** p < 0.001 between MΦ1 and
MΦ2. b: Flow cytometry analysis of MΦ1 and MΦ2 with and without anti-YKL-40 and secondary antibody. Left panel: MΦ1 with secondary
antibody (purple) and MΦ1 with anti-YKL-40 and secondary antibody (black); middle panel: MΦ2 with secondary antibody alone (purple) and
MΦ2 with anti-YKL-40 and secondary antibody (black); right panel: MΦ1 and anti-YKL-40 with secondary antibody (red) and MΦ2 and anti-YKL-40
with secondary antibody (blue). c: YKL-40 secretion in MΦ1 and MΦ2 after 24 and 48 h of stimulation with medium, LPS, TNFα and oncostatin M
(OSM). Data represent mean and SEM of 4 and 3 donors (24 and 48 h, respectively). *: p < 0.001 between MΦ1 and MΦ2 for corresponding
stimulus and time. $: p < 0.001 between corresponding stimulus at different time points. d: Immunofluorescence staining on sputum cytospin of
a COPD patient (blue: DAPI; red: YKL-40; green: CD68)
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Fig. 3 IL-12p40 secretion is dose-dependently inhibited by dexamethasone when added on day 0. IL-10 and IL-12p40 secretion with addition of
dexamethasone at day 0, 3 and 7 of differentiation (0.1, 0.3 and 1nM) (a and b, left, middle and right panel, respectively). Data represent means
and SEM (n = 3 donors). * p≤ 0.05, ** p < 0.01 or *** p < 0.001: between MΦ1 to MΦ2 with corresponding stimulus. $ p ≤ 0.05 or $ p < 0.001
between MΦ1 at different concentrations of dexamethasone
Fig. 4 YKL-40 expression and protein secretion is inhibited by dexamethasone. YKL-40 mRNA levels (normalized expression) and YKL-40 protein
secretion (a and b, respectively) in MΦ1 and MΦ2 with addition of dexamethasone at day 0, 3 and 7 of differentiation (0.1, 0.3 and 1nM)
(left, middle and right panel, respectively). LL-37 mRNA levels (normalized expression) after 0, 3 and 7 days of differentiation with dexamethasone
(0.1, 0.3 and 1nM) (c left, middle and right panel, respectively). Data represent means and SEM (n = 3 donors). * p≤ 0.05, ** p < 0.01 or *** p < 0.001
compared to MΦ2 with corresponding stimulus. $ = p≤ 0.05, $$ p < 0.01 or $$$ p < 0.001 compared to corresponding unstimulated cells. ##: p < 0.01
or ### p < 0.001 compared to corresponding LPS stimulated cells
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(unpublished results). In the present study, we therefore
used LL-37 expression for a comparison with YKL-40
expression. In line with the findings for IL-12p40 and YKL-
40, the expression of LL-37 was also dose-dependently
reduced by increasing doses of dexamethasone when added
on day 0, but not on day 3 or day 7 (Fig. 4c).
Collectively these data indicate that dexamethasone
inhibits YKL-40 expression, but that this effect is most
likely explained by a more generic effect on MΦ1 develop-
ment and is not selective for YKL-40 expression.
YKL-40 expression is not affected by the demethylating
agent 5-AZA
Epigenetic mechanisms may contribute to CHI3L1 ex-
pression. This is supported by the finding of a single-
nucleotide polymorphism (SNP) localized near the CpG
island in the promoter region of the CHI3L1 gene, which
is associated with YKL-40 expression [19, 20]. To eva-
luate whether YKL-40 expression in monocyte-derived
macrophages is influenced by the methylation status of
the CHI3L1 gene, macrophages were generated in the
presence of the demethylating agent 5-AZA. We first
observed that 5-AZA inhibited IL-12p40 secretion, and
to a smaller extent also IL-10 secretion (Fig. 5a and b,
respectively). In contrast, YKL-40 protein secretion
and expression was not significantly affected by 5-
AZA, although it needs to be noted that the highest
concentration resulted in cell toxicity (Fig. 5c and d,
respectively).
YKL-40 levels in serum and sputum of COPD patients are
not changed by treatment with inhaled corticosteroids
We next used samples of the GLUCOLD study to inves-
tigate the effects of ICS treatment on serum and sputum
YKL-40 levels in COPD patients. Baseline characteristics
between the group of moderate-to-severe COPD patients
treated with ICS and placebo were not significantly
different as shown in Table 2. Of the 75 compliant
patients, 70 serum samples and 59 induced sputum
samples at baseline were available and suitable for
analysis. Serum YKL-40 levels at baseline were signifi-
cantly higher compared to sputum levels at baseline
(respectively median 71 ng/ml versus 29 ng/ml, p < 0.001).
ICS treatment did not significantly change YKL-40 levels
in serum and sputum compared to placebo (both p > 0.05;
Fig. 6).
Fig. 5 YKL-40 protein secretion and mRNA expression is inhibited by the demethylating agent 5AZA. IL-10 and IL-12p40 secretion after stimulation
with 5-AZA (concentration 0.1, 1 and 10 μM) (a and b, respectively). YKL-40 protein secretion and mRNA expression in MΦ1 and MΦ2 after culturing
with 5-AZA (concentration 0.1, 0.3 and 1nM) (c and d, respectively). Differentiated cells are stimulated with 100 ng/ml LPS for 24 h. Data represent
mean and SEM (n = 3 donors). * p≤ 0.05, ** p < 0.01 or *** p < 0.001 compared to MΦ2 with corresponding stimulus. # p≤ 0.05, ##: p < 0.01 or
### p < 0.001 compared to corresponding LPS stimulated cells
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Discussion
This study shows that secretion and expression of YKL-
40, a chitinase-like protein, is higher in in vitro generated
monocyte-derived MΦ1 than in MΦ2, and that YKL-40
expression is not further increased upon stimulation with
several pro-inflammatory stimuli. In addition, YKL-40
release in vitro is strongly inhibited by dexamethasone es-
pecially in MΦ1, most likely due to an effect on differenti-
ation. Addition of the demethylating agent 5-AZA did not
significantly decrease YKL-40 release, but did decrease IL-
12p40 production by MΦ1 and to a smaller extent IL-10
production by MΦ2 cells. YKL-40 levels in serum were
significantly higher in serum than in sputum of COPD
patients. Treatment of these patients for 2.5 years
with inhaled corticosteroids did not significantly change
serum and sputum YKL-40 levels compared to placebo.
These results suggest that YKL-40 is a promising pro-
inflammatory marker in in vitro cultured pro-inflammatory
macrophages, but is less suitable for monitoring in vivo
effect of treatment with steroids on YKL-40 in serum
and sputum of COPD patients.
We show that YKL-40 is a novel marker of in vitro
cultured monocyte-derived MΦ1, which is independent
of LPS, OSM and TNFα. This is an important observation,
since many established MΦ1 markers require additional
stimulation to induce expression. Our data confirm and
extend previous results [16, 17, 29], reporting higher
CHI3L1 expression in classically activated macrophages
compared to alternatively activated macrophages. In the
latter studies, in contrast to our study, interferon-gamma
(IFN-γ) and IL-4 were used for MΦ1 and MΦ2 po-
larization, respectively [16, 17]. We extended these data
by differentiating monocytes with GM-CSF and M-CSF
into MΦ1 and MΦ2, respectively, and explored the effect
of further stimulation after differentiation with several
pro-inflammatory stimuli. We found that dexamethasone
efficiently suppressed YKL-40 expression and secretion in
MΦ1, but that this was mainly explained by an inhibitory
effect of dexamethasone on MΦ1differentiation, thus ex-
tending previous results [17].
We found that YKL-40 levels in serum were higher
than in sputum of COPD patients. Serum YKL-40 levels
of our group of patients were comparable with previous
studies [13, 30, 31]. However, sputum YKL-40 levels
with sputum processed using the whole sample method,
were considerably lower than in studies using the se-
lected plug method [12]. This is most likely due to dilu-
tion which is inherent to the whole sample method.
After long-term treatment with ICS, we did not detect a
significant change in YKL-40 levels in serum and spu-
tum compared to placebo. To our knowledge, this is the
first study that evaluates the long-term effect of ICS in
serum and sputum YKL-40 levels of COPD patients.
Therefore, this study presents new in vitro and in vivo
data that may help to provide insight in the function of
YKL-40.
The mechanisms that regulate YKL-40 expression in
health and disease are partly understood. It has been
demonstrated that YKL-40 expression is absent in
monocytes, and markedly induced during macrophage
differentiation, especially during the later stages of differ-
entiation [2]. Promotor analysis of the CHI3L1 gene re-
vealed that especially Sp1, an ubiquitous transcription
factor, is important for CHI3L1 gene expression [6]. Pos-
sibly epigenetic mechanisms also contribute to CHI3L1
expression. This is supported by the finding of a SNP
Table 2 Patient characteristics of compliant patients at baseline
of the GLUCOLD study
ICS (n = 51) Placebo (n = 24)
Gender (M/F) (n) 45/6 20/4
Age (yr) 61.7 (7.8) 59.4 (8.1)
Smoking (y/n) (n) 33/18 17/7
Packyears (yr) 48 (31–56) 42 (34–54)
Post-bronchodilator FEV1 (% pred) 62.5 (9.2) 61.2 (8.3)
Post-bronchodilator FEV1 (L) 2.02 (0.41) 2.00 (0.55)
Post-bronchodilator FEV1/IVC (%) 47.3 (8.8) 46.7 (9.0)
Serum YKL-40 (ng/ml) 66 (49–119) 78 (60–118)
Sputum YKL-40 (ng/ml) 52 (20–79) 18 (12–40)
The ICS group is a combination of the original 30-month fluticasone and
30-month fluticasone with salmeterol groups
Data represent mean with SD, median with interquartile range or numbers
GLUCOLD Groningen and Leiden Universities Corticosteroids in Obstructive
Lung Disease, ICS inhaled corticosteroids, FEV1 forced expiratory volume in 1 s,
IVC inspiratory vital capacity, Pred predicted
Fig. 6 Sputum and serum YKL-40 protein levels of COPD patients
before and after ICS treatment. YKL-40 levels in sputum and serum
at baseline (0) and after 30 months (30 m) of inhaled corticosteroids
(ICS) and placebo. For comparison of the levels between baseline
and 30 months, we only included patients from whom samples
were available at both time points (paired data). Each dot represent
a single patient, red horizontal bars represent medians
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localized near the CpG island in the promoter region of
the CHI3L1 gene, which is associated with YKL-40 ex-
pression [19, 20, 32]. Furthermore, hypomethylation of
the CHI3L1 gene in rheumatoid arthritis is associated
with increased expression of YKL-40 [33, 34]. Therefore,
CHI3L1 gene expression may be regulated by transcrip-
tion factors such as Sp1 and by DNA methylation status.
Our observations with 5-AZA treatment do not support
a role for DNA methylation in the expression of YKL-40
in MΦ1. Further studies into methylation status of the
promotor of YKL-40, the role of histone modification
and microRNAs are needed to define a role of epi-
genetic mechanisms in the expression of YKL-40 in (lung)
macrophages.
The strength of our study is that it describes a thor-
ough evaluation of a novel, potential pro-inflammatory
macrophage marker using both in vitro and in vivo ap-
proaches. Well-characterized patients with COPD used
long-term, randomized, placebo-controlled treatment
with ICS. However, we were unable to detect an effect of
a randomized treatment with ICS on YKL-40 serum and
sputum levels. Nevertheless, our study has some limita-
tions. First, we used in vitro cultured monocyte-derived
macrophages from whole blood of healthy subjects that
were differentiated towards MΦ1 and MΦ2 instead of
lung-derived (e.g. alveolar) macrophages that were differ-
entiated under the influence of the local environment.
Since the culture systems do not fully reflect in vitro dif-
ferentiation of macrophage subsets [35, 36], it needs to
be noted that the effect of steroids on lung macrophages
may differ from that on in vitro differentiated macro-
phages. Furthermore, in vivo a heterogeneous and inter-
mediate macrophage population exists [37], which
complicates the comparison with in vitro generated MΦ
subsets. We therefore cannot formally exclude the possi-
bility that this has contributed to our inability to detect
an effect of inhaled corticosteroids on serum and spu-
tum YKL-40 levels. Second, the demethylating agent
5-AZA demonstrated cell toxicity which might have
influenced our results. However, we found a dose-
dependent inhibition of YKL-40 expression and secretion,
suggesting that DNA methylation status may contribute
to regulation of YKL-40 expression in MΦ1, which is in
line with studies posing that methylation of a part of the
CpG island of the CHI3L1 gene is associated with YKL-40
levels [19, 32].
How can we explain that serum and sputum YKL-40
levels of COPD patients were not significantly changed
after long-term ICS treatment compared to placebo?
This is unexpected since serum YKL-40 levels of rheu-
matoid arthritis patients rapidly decreased after one
week of prednisolone [18]. However, the amount of in-
haled fluticasone that reaches the systemic circulation is
low [38], which could explain why serum YKL-40 levels
did not significantly change with ICS therapy. In addition,
lung macrophages in COPD have reduced glucocorticoid
sensitivity [39, 40].
Conclusions
YKL-40 is mainly expressed and secreted by MΦ1 and is
not further increased by pro-inflammatory stimuli. YKL-
40 release is inhibited by dexamethasone in MΦ1 in vitro,
whereas long-term treatment of COPD patients with in-
haled corticosteroids did not significantly change YKL-40
levels in serum and sputum. This suggests that YKL-40 is
a potential marker for in vitro cultured pro-inflammatory
macrophages and is not a valuable biomarker in serum
and sputum of patients with COPD treated with inhaled
corticosteroids.
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